Search Results - "Vasudev, N S"

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma by Sim, S H, Messenger, M P, Gregory, W M, Wind, T C, Vasudev, N S, Cartledge, J, Thompson, D, Selby, P J, Banks, R E

“…Background: Objectively measured circulating biomarkers of prognosis complementing existing clinicopathological models are needed in renal cell carcinoma…”
Get full text

Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein by Jagdev, S P K, Gregory, W, Vasudev, N S, Harnden, P, Sim, S, Thompson, D, Cartledge, J, Selby, P J, Banks, R E

“…Background: Validated objective biomarkers are needed for patients with renal cell carcinoma (RCC) to guide patient management and define high-risk populations…”
Get full text

Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy by Vasudev, N S, Goh, V, Juttla, J K, Thompson, V L, Larkin, J M G, Gore, M, Nathan, P D, Reynolds, A R

“…Background: We examine how changes in a surrogate marker of tumour vessel density correlate with response and resistance to anti-angiogenic therapy. Methods:…”
Get full text

Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer by Wood, S L, Rogers, M, Cairns, D A, Paul, A, Thompson, D, Vasudev, N S, Selby, P J, Banks, R E

“…Background: In renal cell carcinoma (RCC), the discovery of biomarkers for clinical use is a priority. This study aimed to identify and validate diagnostic and…”
Get full text

Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma by Vasudev, N S, Sim, S, Cairns, D A, Ferguson, R E, Craven, R A, Stanley, A, Cartledge, J, Thompson, D, Selby, P J, Banks, R E

“…Background: No circulating markers are routinely used for renal cancer. The objective of this pilot study was to investigate whether conditioned media (CM)…”
Get full text

Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy by Elumalai, T., Croxford, W., Buijtenhuijs, B., Conroy, R., Sanderson, B., Enting, D., Aversa, C., Doss, G., Das, A., Vasudev, N.S., Kitetere, E., Tolan, S., Law, A., Hoskin, P., Mistry, H., Choudhury, A.

“…Immune checkpoint inhibitors (ICIs) are used in incurable urothelial cancers, both in chemo-naïve and platinum-refractory patients. Efficacy and toxicity data…”
Get full text

Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP) by Gomez de Liano Lista, A., Venugopal, B., Fife, K., Symeonides, S., Vasudev, N.S., Rudman, S.M., Vohra, S., Khasati, L., Pettinger, C., Szabados, B., Morrison, L., Powles, T., Boleti, E.

Get full text

Metastatic clear cell renal cell carcinoma patients with ECOG performance status 2 treated with pazopanib: The Pazo2 trial of efficacy and safety by Porfiri, E., Pirrie, S., Hodgkins, A.-M., Farrugia, D., Fife, K., McDonald-Smith, C., Vasudev, N.S., Nixon, G., James, N.D., Stubbs, C.

Get full text

PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma by Collinson, F., Brown, S., Buckley, H., Ainsworth, G., Howard, H., Poad, H., Carr, G., Banks, R.E., Brown, J., Velikova, G., Larkin, J., Nathan, P., Powles, T.B., Vasudev, N.S.

Get full text

Intravenous Irinotecan Plus Oral Ciclosporin by Vasudev, N.S., Jagdev, S., Anthoney, D.A., Seymour, M.T.

“…We previously reported a phase I study of intravenous irinotecan plus oral ciclosporin, in which dose-limiting diarrhoea was not observed, supporting the…”
Get full text

Aggressive Management of Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis by Vasudev, N.S, Cross, B.A, Snee, M, Joffe, J.K

Get full text

883PMetastatic clear cell renal cell carcinoma patients with ECOG performance status 2 treated with pazopanib: The Pazo2 trial of efficacy and safety by Porfiri, E, Pirrie, S, Hodgkins, A-M, Farrugia, D, Fife, K, McDonald-Smith, C, Vasudev, N S, Nixon, G, James, N D, Stubbs, C

Get full text

893PCabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP) by Gomez de Liano Lista, A, Venugopal, B, Fife, K, Symeonides, S, Vasudev, N S, Rudman, S M, Vohra, S, Khasati, L, Pettinger, C, Szabados, B, Morrison, L, Powles, T, Boleti, E

Get full text

931TiPPRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma by Collinson, F, Brown, S, Buckley, H, Ainsworth, G, Howard, H, Poad, H, Carr, G, Banks, R E, Brown, J, Velikova, G, Larkin, J, Nathan, P, Powles, T B, Vasudev, N S

Get full text

International cancer seminars: a focus on kidney cancer by Scelo, G., Hofmann, J.N., Banks, R.E., Bigot, P., Bhatt, R.S., Cancel-Tassin, G., Chew, S.K., Creighton, C.J., Cussenot, O., Davis, I.J., Escudier, B., Frayling, T.M., Häggström, C., Hildebrandt, M.A.T., Holcatova, I., Johansson, M., Linehan, W.M., McDermott, D.F., Nathanson, K.L., Ogawa, S., Perlman, E.J., Purdue, M.P., Stattin, P., Swanton, C., Vasudev, N.S., Wu, X., Znaor, A., Brennan, P., Chanock, S.J.

“…Recent years have seen important advances in our understanding of the etiology, biology and genetics of kidney cancer. To summarize important achievements and…”
Get full text

Preoperative sodium concentration as a possible predictor of survival in patients with renal cell carcinoma by Vasudev, N. S., Brown, J. E., Brown, S. R., Cocks, K., O'Donnell, D., Patel, P. M., Harnden, P., Banks, R. E., Selby, P. J.

“…Abstract only 10601 Background: Conventional renal cell carcinoma (RCC) has a variable natural history, and determining individual prognosis is important to…”
Get full text

Genomic classification to refine prognosis in clear cell renal cell carcinoma by Glennon, KI, Vasudev, NS, Scelo, G, Wilson, M, Letourneau, L, Eveleigh, R, Nourbehesht, N, Arseneault, M, Paccard, A, Egevad, L, Viksna, J, Celms, E, Jackson, SM, Abedi-Ardekani, B, Warren, AY, Selby, PJ, Trainor, S, Kimuli, M, Soomro, N, Adeyoju, A, Patel, P, Wozniak, MB, Holcatova, I, Brisuda, A, Janout, V, Chanudet, E, Zaridze, D, Moukeria, A, Shangina, O, Foretova, L, Navratilova, M, Mates, D, Jinga, V, Bogdanovic, L, Kovacevic, B, Cambon-Thomsen, A, Bourque, G, Brazma, A, Tost, J, Brennan, P, Lathrop, M, Riazalhosseini, Y, Banks, RE

Get full text

Febrile neutropenia by Naik, Jay D, Sathiyaseelan, Suren R K, Vasudev, Naveen S

Get full text

Delay in the diagnosis of testicular tumours - changes over the past 18 years by Vasudev, Naveen S, Joffe, Johnathan K, Cooke, Carolyn, Richards, Fiona, Jones, William G

“…Delay in the diagnosis of testicular cancer is associated with greater morbidity and poorer prognosis. While the national agenda relates to reducing time to…”
Get full text

Biomarkers of Renal Cancer by Vasudev, N.S., MD, PhD, Banks, R.E., PhD

Get full text